RPg Family Wealth Advisory LLC Has $6.30 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

RPg Family Wealth Advisory LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.8% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 5,991 shares of the biopharmaceutical company’s stock after purchasing an additional 165 shares during the period. Regeneron Pharmaceuticals comprises approximately 1.8% of RPg Family Wealth Advisory LLC’s portfolio, making the stock its 22nd biggest position. RPg Family Wealth Advisory LLC’s holdings in Regeneron Pharmaceuticals were worth $6,298,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brown Lisle Cummings Inc. grew its position in Regeneron Pharmaceuticals by 18.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 10 shares in the last quarter. Sachetta LLC boosted its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the last quarter. Adirondack Trust Co. grew its holdings in shares of Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 10 shares in the last quarter. UMB Bank n.a. increased its position in shares of Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after acquiring an additional 10 shares during the last quarter. Finally, Western Financial Corp CA lifted its holdings in Regeneron Pharmaceuticals by 0.7% during the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock worth $1,912,000 after acquiring an additional 12 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on REGN shares. Barclays decreased their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Finally, BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Trading Up 0.5 %

Regeneron Pharmaceuticals stock opened at $753.03 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The stock has a market cap of $82.75 billion, a P/E ratio of 18.63, a PEG ratio of 2.89 and a beta of 0.15. The firm’s fifty day moving average price is $929.13 and its 200-day moving average price is $1,024.43.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.